AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10692718 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 25 mg
Number of subjects: 257
Study 8591851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of human albumin
Number of subjects: 294
Study 8591851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 1936480 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (short and intermediate‐acting insulin before breakfast and dinner)
Number of subjects: 36
Study 1936480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 21 mg of glibenclamide and 1.5 g of metformin
Number of subjects: 36
Study 1936480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (6 weeks of intermediate and short‐acting insulin 3 times daily)
Number of subjects: 36
Study 1936480 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea therapy (21 mg of glibenclamide/day)
Number of subjects: 36
Study 1936480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent insulin therapy
Number of subjects: 36
Study 7286028 — intervention group
Group type: EXPERIMENTAL
Intervention: medigoxin
Number of subjects: 33
Study 7286028 — intervention group
Group type: COMPARATOR
Intervention: digoxin
Number of subjects: 33
Study 30455233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (two 15-mg/kg doses at least 1 month apart)
Number of subjects: 264
Study 30455233 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 264
Study 29895329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 2000
Study 29895329 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 2000
Study 27225013 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised progesterone (Utrogestan(®), Besins Healthcare) at a dose of 400 mg (two vaginal capsules of 200 mg) administered twice daily from soon after a positive urinary pregnancy test until 12 completed weeks of gestation.
Number of subjects: 836
Study 27225013 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal capsules administered twice daily from soon after a positive urinary pregnancy test until 12 completed weeks of gestation.
Number of subjects: 836
Study 27225013 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 836
Study 27225013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 836
Study 27225013 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analysis
Number of subjects: 836
Study 24090620 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated beer (69mg caffeine/12oz glass)
Number of subjects: 64
Study 24090620 — intervention group
Group type: COMPARATOR
Intervention: Non-caffeinated beer
Number of subjects: 64
Study 22871096 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (PS)
Number of subjects: 507
Study 22871096 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation + food supplementation (PS+FS)
Number of subjects: 507
Study 20237041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation (n = 26)
Number of subjects: 65
Study 20237041 — intervention group
Group type: COMPARATOR
Intervention: Native group (no bowel preparation) (n = 39)
Number of subjects: 65
Study 17345768 — intervention group
Group type: EXPERIMENTAL
Intervention: DD3 mRNA expression in prostate cancer tissues (PCa)
Number of subjects: 102
Study 17345768 — intervention group
Group type: EXPERIMENTAL
Intervention: DD3 mRNA expression in benign prostatic hyperplasia tissues (BPH)
Number of subjects: 102
Study 17345768 — intervention group
Group type: EXPERIMENTAL
Intervention: DD3 mRNA expression in normal prostate tissues (NP)
Number of subjects: 102
Study 17345768 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic value of DD3 mRNA
Number of subjects: 102
Study 17345768 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102
Study 17345768 — intervention group
Group type: COMPARATOR
Intervention: Specificity of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102
Study 17345768 — intervention group
Group type: COMPARATOR
Intervention: Accuracy of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102
Study 17345768 — intervention group
Group type: COMPARATOR
Intervention: Positive predictive value of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102
Study 17345768 — intervention group
Group type: COMPARATOR
Intervention: Negative predictive value of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102
Study 17345768 — intervention group
Group type: COMPARATOR
Intervention: Positive likelihood ratio of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102
Study 17345768 — intervention group
Group type: COMPARATOR
Intervention: Negative likelihood ratio of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102
Study 16252380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (n=50)
Number of subjects: 101
Study 16252380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine-nimodipine (n=50)
Number of subjects: 101
Study 16252380 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine alone (control group, n=51)
Number of subjects: 101
Study 12010353 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PIs)
Number of subjects: 1251
Study 9443470 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d donepezil
Number of subjects: 473
Study 9443470 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d donepezil
Number of subjects: 473
Study 9443470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 7872324 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium dialysate (2.00 mEq/L; LCa)
Number of subjects: 103
Study 7872324 — intervention group
Group type: COMPARATOR
Intervention: Standard calcium dialysate (3.5 mEq/L; SCa)
Number of subjects: 103
Study 30700485 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed total shoulder arthroplasty (RTSA)
Number of subjects: 0
Study 30700485 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 0
Study 30891991 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria elimination assessment in Suzhou City
Number of subjects: 0
Study 30891991 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria elimination review assessment in Wujiang District
Number of subjects: 0
Study 30891991 — intervention group
Group type: COMPARATOR
Intervention: National assessment criteria for malaria elimination
Number of subjects: 0
Study 25613322 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (brisk walking)
Number of subjects: 90
Study 25613322 — intervention group
Group type: COMPARATOR
Intervention: Balance training (balance and strength training)
Number of subjects: 90
Study 24498872 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 0
Study 24498872 — intervention group
Group type: COMPARATOR
Intervention: Treatment choice of supportive care or cytarabine
Number of subjects: 0
Study 23284983 — intervention group
Group type: COMPARATOR
Intervention: Low-to-moderate alcohol drinkers (1 to 2 drinks/day)
Number of subjects: 3088
Study 23284983 — intervention group
Group type: COMPARATOR
Intervention: Heavy drinkers (>3 drinks/day)
Number of subjects: 3088
Study 23284983 — intervention group
Group type: EXPERIMENTAL
Intervention: Male drinkers consuming ≥ 90 g/d (≈8 drinks/d)
Number of subjects: 3088
Study 23284983 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportion of alcohol intake from beer
Number of subjects: 3088
Study 19694743 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib after 5 days treatment with phenytoin (5 mg kg(‐1) daily)
Number of subjects: 18
Study 19694743 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 18
Study 19694743 — intervention group
Group type: COMPARATOR
Intervention: Control phase (gefinitib alone)
Number of subjects: 18
Study 17375635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sedation and topical pharyngeal anesthesia (midazolam 0.035 mg x kg(‐1) and continuous propofol infusion)
Number of subjects: 170
Study 17375635 — intervention group
Group type: COMPARATOR
Intervention: Topical pharyngeal anesthesia alone
Number of subjects: 170
Study 15472672 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of colonic pit patterns by experienced endoscopists using Kudo classification
Number of subjects: 215
Study 15472672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction of histopathology based on pit pattern diagnosis
Number of subjects: 215
Study 11584683 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v.‐thrombolysis with rtPA
Number of subjects: 103
Study 9785068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (40 mg)
Number of subjects: 0
Study 9785068 — intervention group
Group type: COMPARATOR
Intervention: Rectal diclofenac (100 mg)
Number of subjects: 0
Study 7511924 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium supplementation (400 micrograms/d of lithium orally in tablets composed of naturally lithium-rich brewer's yeast for 4 weeks)
Number of subjects: 24
Study 7511924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal, lithium-free brewer's yeast)
Number of subjects: 24
Study 17171950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium with sufentanil (5 microg/kg)
Number of subjects: 24
Study 17171950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium with sufentanil (5 microg/kg)
Number of subjects: 24
Study 17171950 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (in groups B-P and B-V)
Number of subjects: 24
Study 17171950 — intervention group
Group type: COMPARATOR
Intervention: Non-beta-blockers (in groups NB-P and NB-V)
Number of subjects: 24
Study 31923462 — intervention group
Group type: EXPERIMENTAL
Intervention: EtFOSAA
Number of subjects: 397
Study 31923462 — intervention group
Group type: EXPERIMENTAL
Intervention: PFOS
Number of subjects: 397
Study 31923462 — intervention group
Group type: EXPERIMENTAL
Intervention: EtFOSAA-to-PFOS ratio
Number of subjects: 397
Study 29889693 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide (PPS23) vaccine
Number of subjects: 0
Study 29889693 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of pneumococcal conjugate vaccine followed by PPS23 vaccine
Number of subjects: 0
Study 29889693 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual influenza vaccination
Number of subjects: 0
Study 29889693 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccines
Number of subjects: 0
Study 29889693 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent human papillomavirus vaccine
Number of subjects: 0
Study 28588007 — intervention group
Group type: EXPERIMENTAL
Intervention: Education Against Tobacco (EAT) intervention - two medical student-led interactive modules totaling 120 minutes
Number of subjects: 1504
Study 28588007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1504
Study 28588007 — intervention group
Group type: EXPERIMENTAL
Intervention: Education Against Tobacco (EAT) intervention
Number of subjects: 1504
Study 26104826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 17
Study 26104826 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17
Study 24073583 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent SOM
Number of subjects: 67
Study 24073583 — intervention group
Group type: COMPARATOR
Intervention: Non-recurrent SOM
Number of subjects: 67
Study 24073583 — intervention group
Group type: COMPARATOR
Intervention: Simple adenoid hypertrophy
Number of subjects: 67
Study 24073583 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple adenoid hypertrophy (age 3 to 6 subgroup)
Number of subjects: 67
Study 21440829 — intervention group
Group type: EXPERIMENTAL
Intervention: Combigan®
Number of subjects: 30
Study 21440829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19004038 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 98
Study 19004038 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol + calcium
Number of subjects: 98
Study 19004038 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate + calcium
Number of subjects: 98
Study 15990257 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/daily)
Number of subjects: 107
Study 15990257 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MPA (0.625 mg/daily + 2.5 mg/daily)
Number of subjects: 107
Study 15990257 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + NA (0.625 mg/daily + 5 mg/daily)
Number of subjects: 107
Study 15990257 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg once daily)
Number of subjects: 107
Study 15990257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 12829067 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCAB (on-pump)
Number of subjects: 54
Study 12829067 — intervention group
Group type: COMPARATOR
Intervention: OPCAB (off-pump)
Number of subjects: 54
Study 10951278 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreens with SPF 10 (containing organic UV filters or TiO2)
Number of subjects: 0
Study 10951278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo UV exposure of human skin with a single dose of 200 mJ/cm2
Number of subjects: 0
Study 10951278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed epidermal cell lymphocyte reaction
Number of subjects: 0
Study 8899082 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 10 mg
Number of subjects: 24
Study 8899082 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 75 mg
Number of subjects: 24
Study 8899082 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 1801153 — intervention group
Group type: EXPERIMENTAL
Intervention: Amocarzine (3 mg/kg twice daily and postprandial for three consecutive days)
Number of subjects: 148
Study 1801153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 148
Study 6409272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg, 20 mg, and 30 mg three times daily
Number of subjects: 15
Study 6409272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study 30898331 — intervention group
Group type: EXPERIMENTAL
Intervention: MBRP-A (intervention plus usual-care; N = 64)
Number of subjects: 123
Study 30898331 — intervention group
Group type: COMPARATOR
Intervention: Control (usual-care-alone; N = 59)
Number of subjects: 123
Study 30898331 — intervention group
Group type: EXPERIMENTAL
Intervention: MBRP-A
Number of subjects: 123
Study 30898331 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study 28714768 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal
Number of subjects: 24
Study 28714768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornflakes
Number of subjects: 24
Study 28714768 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 24
Study 23959544 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24
Study 23959544 — intervention group
Group type: EXPERIMENTAL
Intervention: S(‐)-amlodipine
Number of subjects: 24
Study 23959544 — intervention group
Group type: COMPARATOR
Intervention: Control (N w‐nitro‐L‐arginine, Ro 31‐8220)
Number of subjects: 24
Study 22019083 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal αTMS
Number of subjects: 78
Study 22019083 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal αTMS
Number of subjects: 78
Study 22019083 — intervention group
Group type: COMPARATOR
Intervention: Frontal sham
Number of subjects: 78
Study 22019083 — intervention group
Group type: COMPARATOR
Intervention: Parietal sham
Number of subjects: 78
Study 22019083 — intervention group
Group type: EXPERIMENTAL
Intervention: αTMS with concomitant typical neuroleptics
Number of subjects: 78
Study 22019083 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG normalization (Q factor increase)
Number of subjects: 78
Study 20415370 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive total knee arthroplasty
Number of subjects: 0
Study 20415370 — intervention group
Group type: COMPARATOR
Intervention: Traditional total knee arthroplasty
Number of subjects: 0
Study 18030197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-spatial-resolution MR imaging at 3 Tesla
Number of subjects: 18
Study 15013654 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted behavioral therapy
Number of subjects: 0
Study 15013654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin therapy
Number of subjects: 0
Study 15013654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (both drug and behavioral therapy)
Number of subjects: 0
Study 15013654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11396779 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg selenium as L-selenomethionine during pregnancy and 12 months postpartum
Number of subjects: 52
Study 11396779 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy and 12 months postpartum
Number of subjects: 52
Study 11396779 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg selenium as L-selenomethionine for non-pregnant women
Number of subjects: 52
Study 9734726 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 6
Study 7753720 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS educational programs (specific types not detailed)
Number of subjects: 497
Study 7753720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-test counseling
Number of subjects: 497
Study 2661231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone single dose plus metronidazole
Number of subjects: 60
Study 2661231 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime multiple doses plus metronidazole
Number of subjects: 60
Study 130835 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium sulfide shampoo
Number of subjects: 0
Study 130835 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied amphotericin
Number of subjects: 0
Study 130835 — intervention group
Group type: COMPARATOR
Intervention: Suppression of scalp microorganisms
Number of subjects: 0
Study 30545967 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachute
Number of subjects: 23
Study 30545967 — intervention group
Group type: COMPARATOR
Intervention: Empty backpack (control)
Number of subjects: 23
Study 28459238 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney reinforcing and Qi tonifying (KQ)
Number of subjects: 111
Study 28459238 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney reinforcing and blood circulation invigorating (KC)
Number of subjects: 111
Study 28459238 — intervention group
Group type: EXPERIMENTAL
Intervention: All treated groups
Number of subjects: 111
Study 25606338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioptron light therapy (8 sessions, 3 times a week)
Number of subjects: 44
Study 25606338 — intervention group
Group type: COMPARATOR
Intervention: Wrist splinting
Number of subjects: 44
Study 22822024 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐γ (100 μg/day)
Number of subjects: 18
Study 22822024 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (4 μg/kg/day)
Number of subjects: 18
Study 22822024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 18
Study 20650377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 0.5 mg neostigmine
Number of subjects: 40
Study 20650377 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with isotonic saline
Number of subjects: 40
Study 18757948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 3146
Study 18757948 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3146
Study 15977590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (any type)
Number of subjects: 248
Study 15977590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (perpetration)
Number of subjects: 248
Study 15977590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual violence (experienced)
Number of subjects: 248
Study 15977590 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical, sexual, and psychological violence (perpetration)
Number of subjects: 248
Study 15977590 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to violence in family of origin
Number of subjects: 248
Study 12873857 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride, 100 mg 3 times daily for 2 weeks
Number of subjects: 24
Study 12873857 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 24
Study 12873857 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine therapy
Number of subjects: 24
Study 12873857 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 24
Study 11429003 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (2 g daily for 2-3 months) following 14-21 days of intravenous ganciclovir (5 mg/kg b.i.d.)
Number of subjects: 37
Study 11429003 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg b.i.d. for 14-21 days)
Number of subjects: 37
Study 8785142 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous non-invasive arterial pressure measurement (CNAP)
Number of subjects: 22
Study 8785142 — intervention group
Group type: COMPARATOR
Intervention: Oscillometric measurements
Number of subjects: 22
Study 8785142 — intervention group
Group type: EXPERIMENTAL
Intervention: CNAP during induction of anaesthesia
Number of subjects: 22
Study 1998761 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2‐8 mg daily
Number of subjects: 50
Study 1998761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20‐80 mg daily
Number of subjects: 50
Study 1998761 — intervention group
Group type: COMPARATOR
Intervention: Both drugs (Perindopril and Nifedipine)
Number of subjects: 50
Study 6689152 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Pro‐Banthine 15 mg tablets
Number of subjects: 6
Study 6689152 — intervention group
Group type: COMPARATOR
Intervention: Developmental PA Pro‐Banthine 45 mg capsule
Number of subjects: 6